Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | GMNN | O75496 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827 | 1.00 | — | — | |
| SCHEMBL8780216 | 0.96 | LMNA (0.47) | LMNABLMPTGS1PDE4ASLC6A6 | |
| SCHEMBL1177405 | 0.96 | — | — | |
| Sulfuric Acid SCHEMBL9751183 | 0.96 | LMNA (0.47) | LMNABLMPTGS1PDE4ASLC6A6 | |
| SCHEMBL1138826 | 0.96 | — | — | |
| SCHEMBL11516591 | 0.96 | LMNA (0.47) | LMNABLMPTGS1PDE4ASLC6A6 | |
| SCHEMBL1138506 | 0.96 | — | — | |
| SCHEMBL1304651 | 0.96 | — | — | |
| Bromide SCHEMBL20595015 | 0.96 | — | — | |
| SCHEMBL9001614 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 316 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680182-A1 | NEW SOLID COSMETIC COMPOSITIONS AND USE THEREOF FOR HYGIENE OF THE SKIN OR HAIR | Pierre Fabre Dermo-Cosmétique (FR) | 2026-01-21 | — | — | EP | disclosed |
| CN-119033822-A | Compositions and methods for inhibiting seizures | 加利福尼亚大学董事会 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024189052-A1 | NEW SOLID COSMETIC COMPOSITIONS AND USE THEREOF FOR HYGIENE OF THE SKIN OR HAIR | Pierre Fabre Dermo-Cosmétique (FR) | 2024-09-19 | — | — | WO | disclosed |
| CN-110325196-B | Compositions and methods for inhibiting seizures | 加利福尼亚大学董事会 | 2024-08-27 | — | — | CN | disclosed |
| CN-111801121-B | 2-PMPA prodrugs for healthy tissue protection during PSMA-targeted cancer imaging or radiation therapy | 约翰霍普金斯大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-117062607-A | Methyl substituted pyridine and pyridazine compounds, derivatives thereof and methods of use thereof | 拉堤果生物医疗股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230277484-A1 | COMPOSITIONS AND METHODS TO PROMOTE BRAIN HEALTH | Guardian Biosciences, LLC (US) | 2023-09-07 | — | — | US | disclosed |
| WO-2023167989-A2 | COMPOSITIONS AND METHODS TO PROMOTE BRAIN HEALTH | Guardian Biosciences, LLC (US) | 2023-09-07 | — | — | WO | disclosed |
| EP-3322417-B1 | TARGETING EMOPAMIL BINDING PROTEIN (EBP) WITH SMALL MOLECULES THAT INDUCE AN ABNORMAL FEEDBACK RESPONSE BY LOWERING ENDOGENOUS CHOLESTEROL BIOSYNTHESIS | UNIV TEXAS (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11725056-B2 | Methods for targeting the immune checkpoint PD1 pathway for treating pulmonary fibrosis | CEDARS-SINAI MEDICAL CENTER (US) | 2023-08-15 | — | — | US | disclosed |
| US-20070191371-A1 | HETEROCYCLIC MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-7235661-B2 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBOTT LABORATORIES (US) | 2007-06-26 | — | — | US | disclosed |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | ABBVIE INC. | 2006-11-23 | — | — | US | disclosed |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | ABBVIE INC. | 2006-09-07 | — | — | US | disclosed |
| US-20060199864-A1 | Selection of pH-dependent compounds for in vivo therapy | EMORY UNIVERSITY | 2006-09-07 | — | — | US | disclosed |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| EP-1643948-A1 | DIFFUSION LAYER MODULATED SOLIDS | Pharmacia & Upjohn Company LLC (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050042291-A1 | Diffusion layer modulated solids | HAWLEY MICHAEL (US) | 2005-02-24 | — | — | US | disclosed |
| WO-2005004763-A1 | DIFFUSION LAYER MODULATED SOLIDS | PHARMACIA & UPJOHN COMPANY LLC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-6008303-A | Polymers suitable as dispersing resins | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191371-A1 | HETEROCYCLIC MODULATORS OF PPAR | PPARG, PPARD, PPARA | LMNA 2210/4885BLM 3393/4885PTGS1 335/4885 |
| US-20060199851-A1 | Novel compounds that are useful for improving pharmacokinetics | CYP11B1, CYP11B2, CYP7A1 | LMNA 4776/4885BLM 4111/4885PTGS1 125/4885 |
| US-20060172995-A1 | Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction | CYP19A1, CYP17A1, DDC | LMNA 3391/4885BLM 1350/4885PTGS1 1535/4885 |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | FNTB, FNTA, FDPS | LMNA 3187/4885BLM 3079/4885PTGS1 1334/4885 |
| US-20060199864-A1 | Selection of pH-dependent compounds for in vivo therapy | PHGDH, ASAH2, HRH2 | LMNA 2505/4885BLM 2594/4885PTGS1 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.